- Home
- HRTX
as 07-26-2024 4:00pm EST
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 432.4M | IPO Year: | 1987 |
| Target Price: | $6.00 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.50 - $3.93 | Next Earning Date: | 08-12-2024 |
| Revenue: | $132,099,000 | Revenue Growth: | 16.05% |
| Revenue Growth (this year): | 18.71% | Revenue Growth (next year): | 20.34% |
Stock Insider Trading Activity of Heron Therapeutics Inc. (HRTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Forbes William P | HRTX | EVP, Chief Development Officer | Nov 17 '23 | Buy | $1.09 | 25,000 | $27,250.00 | 79,000 | SEC Form 4 |
| Collard Craig A | HRTX | Chief Executive Officer | Nov 16 '23 | Buy | $0.92 | 150,000 | $137,970.00 | 186,496 | SEC Form 4 |
| Forbes William P | HRTX | EVP, Chief Development Officer | Nov 16 '23 | Buy | $0.94 | 50,000 | $46,995.00 | 54,000 | SEC Form 4 |
| Duarte Ira | HRTX | EVP, Chief Financial Officer | Nov 16 '23 | Buy | $0.89 | 85,000 | $75,599.00 | 85,000 | SEC Form 4 |
Latest Heron Therapeutics Inc. News
HRTX Breaking Stock News: Dive into HRTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
While shareholders of Heron Therapeutics (NASDAQ:HRTX) are in the black over 1 year, those who bought a week ago aren't so fortunate
MT Newswires
11 days ago
Heron Therapeutics Says Non-Opioid Pain Medication to be Included in Proposed Medicare Programs
PR Newswire
11 days ago
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
Zacks
15 days ago
Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know
Zacks
16 days ago
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
MT Newswires
24 days ago
Heron Reports Acceptance of Prior Approval Supplement Application for Zynrelef Vial Access Needle
Zacks
24 days ago
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
PR Newswire
24 days ago
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
Compare HRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HRTX Heron Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.